Hiroshi Arakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hiroshi Arakawa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Fumiyoshi Yamashita
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501, Japan
1 shared publicationHiroki Kamioka
Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi Takasaki-shi, Gunma, 370-0033, Japan
1 shared publicationKaori Morimoto
Department of Drug Absorption and Pharmacokinetics, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aobaku, Sendai, Miyagi, 981-8558, Japan
1 shared publication- Kaori Morimoto
Department of Drug Absorption and Pharmacokinetics, Tohoku Pharmaceutical University, Sendai, Miyagi, 981-8558, Japan
1 shared publication Kentaro Yano
Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi Takasaki-shi, Gunma, 370-0033, Japan
1 shared publication- Kentaro Yano
Laboratory of Biopharmaceutics, Department of Pharmacology, Takasaki University of Health and Welfare, Takasaki, Gunma, Japan
1 shared publication
Latest Publications
- 21 November 2015
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (1) , 39-45
Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide‐mimetic drugs
The study investigated whether quinolone antibiotics inhibit the PEPT1‐mediated uptake of its substrates. Among the quinolones examined, lomefloxacin, moxifloxacin (MFLX) and purlifloxacin significantly inhibited the uptake of PEPT1 substrate phenylalanine‐Ψ(CN‐S)‐alanine (Phe‐Ψ‐Ala) in HeLa/PEPT1 cells to 31.6 ± 1.3%, 27.6 ± 2.9%, 36.8 ± 2.2% and 32.6 ± 1.4%, respectively. Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50value of 4.29 ± 1.29 mm. In addition, MFLX significantly decreased the cephalexin and valacyclovir uptake in HeLa/PEPT1 cells. In anin vivostudy in rats, the maximum plasma concentration (Cmax) of orally administered Phe‐Ψ‐Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml). The area under the concentration–time curve (AUC) of orally administered Phe‐Ψ‐Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h). The oral bioavailability of Phe‐Ψ‐Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively. The results indicate that administration of quinolone antibiotics concomitantly with PEPT1 substrate drugs may potentially result in drug–drug interaction. Copyright © 2016 John Wiley & Sons, Ltd.
- 21 November 2015
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (1) , 39-45
Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide‐mimetic drugs
The study investigated whether quinolone antibiotics inhibit the PEPT1‐mediated uptake of its substrates. Among the quinolones examined, lomefloxacin, moxifloxacin (MFLX) and purlifloxacin significantly inhibited the uptake of PEPT1 substrate phenylalanine‐Ψ(CN‐S)‐alanine (Phe‐Ψ‐Ala) in HeLa/PEPT1 cells to 31.6 ± 1.3%, 27.6 ± 2.9%, 36.8 ± 2.2% and 32.6 ± 1.4%, respectively. Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50value of 4.29 ± 1.29 mm. In addition, MFLX significantly decreased the cephalexin and valacyclovir uptake in HeLa/PEPT1 cells. In anin vivostudy in rats, the maximum plasma concentration (Cmax) of orally administered Phe‐Ψ‐Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml). The area under the concentration–time curve (AUC) of orally administered Phe‐Ψ‐Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h). The oral bioavailability of Phe‐Ψ‐Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively. The results indicate that administration of quinolone antibiotics concomitantly with PEPT1 substrate drugs may potentially result in drug–drug interaction. Copyright © 2016 John Wiley & Sons, Ltd.
- 1 September 2015
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (9) , 2789-2794
Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity Measured with a Sensor
- 1 September 2015
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (9) , 2789-2794
Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity Measured with a Sensor